ArticleFrontiers in pharmacology2023

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective.

Kexun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.